FEATURED BLOGS
Aug 10, 2017
In a divisive time, I look to my patients and see that there is more that unites us than divides us, and this is worth celebrating.
Aug 04, 2017
Never doubt that your voice and time matter when it comes to trying to change the world in a positive way. We as a community can come together and really make a difference, and you can see it...
Aug 03, 2017
The program is now available for this year's Research Community Forum Annual Meeting. Dr. Richard L. Schilsky invites you to join this unique event on September 24-25 in Alexandria, VA.
Aug 03, 2017
When accommodating the needs of an anxious patient, some would suggest that I am aiding and abetting a maladaptive coping style and that I am not helping him at all. But for me, this is the...
Aug 01, 2017
Yes, "at least" my patient was still alive. But, at the end of the day, I knew that would not be comforting. “At least” is never enough, because when it comes to life, most of us—cancer or no cancer—...
Jul 26, 2017
My coauthors and I identify deficiencies in prevention and screening efforts that could be acted upon to further reduce cervical cancer incidence and mortality in Latin America.
Jul 24, 2017
Dr. Nagi El Saghir, Dr. Sana Al-Sukhun, and Dr. Joseph Makdessi share highlights of the Best of ASCO Lebanon meeting, attended by more than 300 health care professionals from the Middle East, Europe...

Latest Comments & Discussions


ASCO International Affairs
Aug 16, 2017

In 2016, ASCO partnered with the Middle East Cancer Consortium to hold an International Palliative Care Workshop in Almaty, Kazakhstan...


Anis Toumeh, MD
Aug 14, 2017
1- Mechanisms of acquired resistance to crizotinib typically involve changes in the ALK gene or activation of signaling pathways...

Christine Marie Lovly, MD, PhD
Aug 14, 2017
Course Faculty Response Thank you for the question! The results from the Global ALEX study were recently published (Peters, 2017). At...

Shrinkhala Khanna, MD
Aug 14, 2017
Ceritinib and alectinib can both be used. My preferred drug would be alectinib. Beaded on the ALEX data- alectinib should now be first line...

ASCO University
Aug 14, 2017
Discussion Questions 1. What are mechanisms of acquired resistance to crizotinib? 2. What treatment would you offer for second-line...

Pages

Most Read

Yes, "at least" my patient was still alive. But, at the end of the day, I knew that would not be comforting. “At least” is never enough, because when it comes to life, most of us—cancer or no cancer—always want more.
When accommodating the needs of an anxious patient, some would suggest that I am aiding and abetting a maladaptive coping style and that I am not helping him at all. But for me, this is the definition of patient-centered care.
The program is now available for this year's Research Community Forum Annual Meeting. Dr. Richard L. Schilsky invites you to join this unique event on September 24-25 in Alexandria, VA.
Read more to answer the following questions: 1) What are acceptable approaches for ALK testing? 2) What systemic therapy would you offer?
Never doubt that your voice and time matter when it comes to trying to change the world in a positive way. We as a community can come together and really make a difference, and you can see it firsthand any weekend in almost any city across the country.

Tweets from ASCO

Tweets from Oncology Community